BACKGROUND: Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such individuals. We thus aimed to examine the association between the cognitive status of participants (amnestic mild cognitive impairment (aMCI-AD) vs cognitively normal (CN) older adults) and MBI severity. Within aMCI-AD, we further examined the association between APOE and BDNF risk genetic polymorphisms and MBI severity. METHODS: We included 62 aMCI-AD participants and 50 CN older adults from the Czech Brain Aging Study. The participants underwent neurological, comprehensive neuropsychological examination, APOE and BDNF genotyping, and magnetic resonance imaging. MBI was diagnosed with the Mild Behavioral Impairment Checklist (MBI-C), and the diagnosis was based on the MBI-C total score ≥ 7. Additionally, self-report instruments for anxiety (the Beck Anxiety Inventory) and depressive symptoms (the Geriatric Depression Scale-15) were administered. The participants were stratified based on the presence of at least one risk allele in genes for APOE (i.e., e4 carriers and non-carriers) and BDNF (i.e., Met carriers and non-carriers). We used linear regressions to examine the associations. RESULTS: MBI was present in 48.4% of the aMCI-AD individuals. Compared to the CN, aMCI-AD was associated with more affective, apathy, and impulse dyscontrol but not social inappropriateness or psychotic symptoms. Furthermore, aMCI-AD was related to more depressive but not anxiety symptoms on self-report measures. Within the aMCI-AD, there were no associations between APOE e4 and BDNF Met and MBI-C severity. However, a positive association between Met carriership and self-reported anxiety appeared. CONCLUSIONS: MBI is frequent in aMCI-AD and related to more severe affective, apathy, and impulse dyscontrol symptoms. APOE and BDNF polymorphisms were not associated with MBI severity separately; however, their combined effect warrants further investigation.

Center for Innovation in Healthy and Resilient Aging Edson College of Nursing and Health Innovation Arizona State University Phoenix AZ USA

Clinical and Biomedical Sciences Faculty of Health and Life Sciences University of Exeter Exeter United Kingdom

Department of Clinical Biochemistry Hematology and Immunology Homolka Hospital Prague Czech Republic

Department of Clinical Psychology Motol University Hospital Prague Czech Republic

Department of Neurology Memory Clinic Charles University 2nd Faculty of Medicine and Motol University Hospital 5 Uvalu 84 150 06 Prague Czech Republic

Departments of Psychiatry and Clinical Neurosciences Cumming School of Medicine Hotchkiss Brain Institute University of Calgary Calgary AB Canada

International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Women's Operational Military Exposure Network VA Palo Alto Health Care System Palo Alto CA USA

See more in PubMed

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi: 10.1016/j.jalz.2011.03.005. PubMed DOI PMC

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. doi: 10.1016/j.jalz.2011.03.008. PubMed DOI PMC

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018. PubMed DOI PMC

Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement (Amst) 2019;18(11):333–339. doi: 10.1016/j.dadm.2019.02.006. PubMed DOI PMC

Roberto N, Portella MJ, Marquié M, Alegret M, Hernández I, Mauleón A, et al. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep. 2021;11(1):6448. doi: 10.1038/s41598-021-83126-y. PubMed DOI PMC

Paradise M, McCade D, Hickie IB, Diamond K, Lewis SJG, Naismith SL. Caregiver burden in mild cognitive impairment. Aging Ment Health. 2015;19(1):72–78. doi: 10.1080/13607863.2014.915922. PubMed DOI

Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202. doi: 10.1016/j.jalz.2015.05.017. PubMed DOI PMC

Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis. 2017;56(3):929–938. doi: 10.3233/JAD-160979. PubMed DOI PMC

Hu S, Patten S, Charlton A, Fischer K, Fick G, Smith EE, et al. Validating the mild behavioral impairment checklist in a cognitive clinic: comparisons with the Neuropsychiatric Inventory Questionnaire. J Geriatr Psychiatry Neurol. 2022;17:08919887221093353. PubMed PMC

Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the Mild Behavioral Impairment-Checklist in people with mild cognitive impairment. J Alzheimers Dis. 2018;66(1):83–95. doi: 10.3233/JAD-180131. PubMed DOI

Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. Int Psychogeriatr. 2018;18:1–9. PubMed

Eikelboom WS, van den Berg E, Singleton EH, Baart SJ, Coesmans M, Leeuwis AE, et al. Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations. Neurology. 2021;97(13):e1276–e1287. doi: 10.1212/WNL.0000000000012598. PubMed DOI PMC

Wang Y, Lou F, Li Y, Liu F, Wang Y, Cai L, et al. Clinical, neuropsychological, and neuroimaging characteristics of amyloid-positive vs. amyloid-negative patients with clinically diagnosed Alzheimer’s disease and amnestic mild cognitive impairment. Curr Alzheimer Res. 2021;18(6):523–532. doi: 10.2174/1567205018666211001113349. PubMed DOI

Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–16. PubMed

Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5(1–2):165–173.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. doi: 10.1037/0022-006X.56.6.893. PubMed DOI

Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: a systematic literature review. Neurosci Biobehav Rev. 2019;1(107):346–359. doi: 10.1016/j.neubiorev.2019.09.014. PubMed DOI

Ng KP, Chiew H, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Transl Neurodegener. 2021;10(1):11. doi: 10.1186/s40035-021-00236-3. PubMed DOI PMC

Mortby ME, Ismail Z, Anstey KJ. Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr. 2018;30(2):221–232. doi: 10.1017/S1041610217001909. PubMed DOI

Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr. 2018;30(2):233–244. doi: 10.1017/S104161021700151X. PubMed DOI

Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):2. doi: 10.1186/s13195-021-00949-7. PubMed DOI PMC

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–608. doi: 10.1016/j.jalz.2012.12.001. PubMed DOI PMC

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118. doi: 10.1038/nrneurol.2012.263. PubMed DOI PMC

Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400. doi: 10.1146/annurev.med.47.1.387. PubMed DOI

Joie RL, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96(5):e650–e661. PubMed PMC

Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, et al. Cognitive subtypes of probable Alzheimer’s disease robustly identified in four cohorts. Alzheimers Dement. 2017;13(11):1226–1236. doi: 10.1016/j.jalz.2017.03.002. PubMed DOI PMC

Weintraub S, Teylan M, Rader B, Chan KCG, Bollenbeck M, Kukull WA, et al. APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. Neurology. 2020;94(6):e607–e612. doi: 10.1212/WNL.0000000000008666. PubMed DOI PMC

Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010;7(2):158–164. doi: 10.2174/156720510790691173. PubMed DOI

Panza F, Frisardi V, Seripa D, D’Onofrio G, Santamato A, Masullo C, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev. 2012;11(1):87–103. doi: 10.1016/j.arr.2011.06.005. PubMed DOI

Tsang RSM, Mather KA, Sachdev PS, Reppermund S. Systematic review and meta-analysis of genetic studies of late-life depression. Neurosci Biobehav Rev. 2017;75:129–139. doi: 10.1016/j.neubiorev.2017.01.028. PubMed DOI

Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer’s disease dementia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;1(96):302–315. doi: 10.1016/j.neubiorev.2018.11.020. PubMed DOI

Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, et al. β-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. Am J Geriatr Psychiatry. 2016;24(12):1191–1195. doi: 10.1016/j.jagp.2016.08.007. PubMed DOI

Andrews SJ, Ismail Z, Anstey KJ, Mortby M. Association of Alzheimer’s genetic loci with mild behavioral impairment. Am J Med Genet B Neuropsychiatr Genet. 2018;177(8):727–735. doi: 10.1002/ajmg.b.32684. PubMed DOI

Vellone D, Ghahremani M, Goodarzi Z, Forkert ND, Smith EE, Ismail Z. Apathy and APOE in mild behavioral impairment, and risk for incident dementia. Alzheimers Dement (N Y) 2022;8(1):e12370. doi: 10.1002/trc2.12370. PubMed DOI PMC

Brown DT, Vickers JC, Stuart KE, Cechova K, Ward DD. The BDNF Val66Met polymorphism modulates resilience of neurological functioning to brain ageing and dementia: a narrative review. Brain Sci. 2020;10(4):195. doi: 10.3390/brainsci10040195. PubMed DOI PMC

Pei Y, Smith AK, Wang Y, Pan Y, Yang J, Chen Q, et al. The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):560–566. doi: 10.1002/ajmg.b.32062. PubMed DOI PMC

Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, et al. Trajectories of depressive symptoms before diagnosis of dementia. JAMA Psychiat. 2017;74(7):712–718. doi: 10.1001/jamapsychiatry.2017.0660. PubMed DOI PMC

Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–275. doi: 10.3233/JAD-2012-111922. PubMed DOI PMC

Tapiainen V, Hartikainen S, Taipale H, Tiihonen J, Tolppanen AM. Hospital-treated mental and behavioral disorders and risk of Alzheimer’s disease: a nationwide nested case-control study. Eur Psychiatry. 2017;43:92–98. doi: 10.1016/j.eurpsy.2017.02.486. PubMed DOI

Borroni B, Archetti S, Costanzi C, Grassi M, Ferrari M, Radeghieri A, et al. Role of BDNF Val66Met functional polymorphism in Alzheimer’s disease-related depression. Neurobiol Aging. 2009;30(9):1406–1412. doi: 10.1016/j.neurobiolaging.2007.11.023. PubMed DOI

Zhang L, Fang Y, Zeng Z, Lian Y, Wei J, Zhu H, et al. BDNF gene polymorphisms are associated with Alzheimer’s disease-related depression and antidepressant response. J Alzheimers Dis. 2011;26(3):523–530. doi: 10.3233/JAD-2011-110113. PubMed DOI

Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, et al. Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. Int J Geriatr Psychiatry. 2018;33(2):405–413. doi: 10.1002/gps.4761. PubMed DOI PMC

Nagata T, Kobayashi N, Shinagawa S, Yamada H, Kondo K, Nakayama K. Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. J Neural Transm. 2014;121(4):433–441. doi: 10.1007/s00702-013-1121-y. PubMed DOI

Cechova K, Andel R, Angelucci F, Chmatalova Z, Markova H, Laczó J, et al. Impact of APOE and BDNF Val66Met gene polymorphisms on cognitive functions in patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2020;73(1):247–257. doi: 10.3233/JAD-190464. PubMed DOI

Laczó J, Cechova K, Parizkova M, Lerch O, Andel R, Matoska V, et al. The combined effect of APOE and BDNF Val66Met polymorphisms on spatial navigation in older adults. J Alzheimers Dis. 2020;78(4):1473–1492. doi: 10.3233/JAD-200615. PubMed DOI PMC

Matuskova V, Ismail Z, Nikolai T, Markova H, Cechova K, Nedelska Z, et al. Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. Front Aging Neurosci. 2021;24(13):643271. doi: 10.3389/fnagi.2021.643271. PubMed DOI PMC

Sheardova K, Vyhnalek M, Nedelska Z, Laczo J, Andel R, Marciniak R, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open. 2019;9(12):e030379. doi: 10.1136/bmjopen-2019-030379. PubMed DOI PMC

Nikolai T, Stepankova H, Kopecek M, Sulc Z, Vyhnalek M, Bezdicek O. The uniform data set, Czech version: normative data in older adults from an international perspective. J Alzheimers Dis. 2018;61(3):1233–1240. doi: 10.3233/JAD-170595. PubMed DOI PMC

Nikolai T, Štěpánková H, Michalec J, Bezdíček O, Horáková K, Marková H, et al. Verbal Fluency Tests – Czech normative study for older persons. Cesk Slov Neurol N. 2015;78(111):292–299. doi: 10.14735/amcsnn2015292. DOI

Drozdová K, Štěpánková H, Lukavský J, Bezdíček O, Kopeček M. Normative data for the Rey- Osterrieth Complex Figure Test in older Czech adults. Cesk Slov Neurol N. 2015;78(111):542–549.

Bezdicek O, Lukavsky J, Stepankova H, Nikolai T, Axelrod BN, Michalec J, et al. The Prague Stroop Test: normative standards in older Czech adults and discriminative validity for mild cognitive impairment in Parkinson’s disease. J Clin Exp Neuropsychol. 2015;37(8):794–807. doi: 10.1080/13803395.2015.1057106. PubMed DOI

Matuskova V, Nikolai T, Markova H, Cechova K, Laczo J, Hort J, et al. Neuropsychiatrické symptomy jako časná manifestace Alzheimerovy nemoci. Cesk Slov Neurol N. 2020;83(1):64–72.

Kassam F, Chen H, Nosheny RL, McGirr A, Williams T, Ng N, et al. Cognitive profile of people with mild behavioral impairment in Brain Health Registry participants. Int Psychogeriatr. 2022;8:1–10. PubMed PMC

Ghahremani M, Nathan S, Smith EE, McGirr A, Goodyear B, Ismail Z. Functional connectivity and mild behavioral impairment in dementia-free elderly. Alzheimers Dement. 2023;9(1):e12371. doi: 10.1002/trc2.12371. PubMed DOI PMC

Creese B, Arathimos R, Brooker H, Aarsland D, Corbett A, Lewis C, et al. Genetic risk for Alzheimer’s disease, cognition, and mild behavioral impairment in healthy older adults. Alzheimers Dement. 2021;13(1):e12164. PubMed PMC

Gitlin LN, Marx KA, Stanley IH, Hansen BR, Van Haitsma KS. Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. Int Psychogeriatr. 2014;26(11):1805–1848. doi: 10.1017/S1041610214001537. PubMed DOI PMC

Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545–548. doi: 10.1016/S0022-2275(20)43176-1. PubMed DOI

Laczó J, Andel R, Vlček K, Macoška V, Vyhnálek M, Tolar M, et al. Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis. 2011;8(4):169–177. doi: 10.1159/000321581. PubMed DOI

Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8(1):65–73. doi: 10.1016/j.jalz.2011.07.004. PubMed DOI

Belohlavek O, Jaruskova M, Skopalova M, Szarazova G, Simonova K. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging. 2019;46(2):297–303. doi: 10.1007/s00259-018-4140-y. PubMed DOI PMC

Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z, et al. Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease. Neurology. 2023;100(7):e683–e693. doi: 10.1212/WNL.0000000000201517. PubMed DOI PMC

Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavioral impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16(1):192–199. doi: 10.1002/alz.12007. PubMed DOI PMC

Johansson M, Stomrud E, Insel PS, Leuzy A, Johansson PM, Smith R, et al. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease. Transl Psychiatry. 2021;11(1):76. doi: 10.1038/s41398-021-01206-z. PubMed DOI PMC

Kianimehr G, Fatehi F, Noroozian M. Prevalence of mild behavioral impairment in patients with mild cognitive impairment. Acta Neurol Belg. 2022;122:1493–7.10.1007/s13760-021-01724-z. PubMed

Pan Y, Shea YF, Li S, Chen R, Mak HKF, Chiu PKC, et al. Prevalence of mild behavioural impairment: a systematic review and meta-analysis. Psychogeriatrics. 2021;21(1):100–111. doi: 10.1111/psyg.12636. PubMed DOI

Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJH, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65(10):1193–1198. doi: 10.1001/archpsyc.65.10.1193. PubMed DOI PMC

Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685–695. doi: 10.1016/j.jagp.2013.01.006. PubMed DOI PMC

Sugarman MA, Alosco ML, Tripodis Y, Steinberg EG, Stern RA. Neuropsychiatric symptoms and the diagnostic stability of mild cognitive impairment. J Alzheimers Dis. 2018;62(4):1841–1855. doi: 10.3233/JAD-170527. PubMed DOI PMC

Desmarais P, Lanctôt KL, Masellis M, Black SE, Herrmann N. Social inappropriateness in neurodegenerative disorders. Int Psychogeriatr. 2018;30(2):197–207. doi: 10.1017/S1041610217001260. PubMed DOI

Fischer CE, Agüera-Ortiz L. Psychosis and dementia: risk factor, prodrome, or cause? Int Psychogeriatr. 2018;30(2):209–219. doi: 10.1017/S1041610217000874. PubMed DOI

Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, et al. Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities. Nat Rev Neurol. 2022;18(3):131–144. doi: 10.1038/s41582-021-00597-3. PubMed DOI PMC

Dietlin S, Soto M, Kiyasova V, Pueyo M, de Mauleon A, Delrieu J, et al. Neuropsychiatric symptoms and risk of progression to Alzheimer’s disease among mild cognitive impairment subjects. J Alzheimers Dis. 2019;70(1):25–34. doi: 10.3233/JAD-190025. PubMed DOI

Ismail Z, Elbayoumi H, Fischer CE, Hogan DB, Millikin CP, Schweizer T, et al. Prevalence of depression in patients with mild cognitive impairment: a systematic review and meta-analysis. JAMA Psychiat. 2017;74(1):58–67. doi: 10.1001/jamapsychiatry.2016.3162. PubMed DOI

Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease. Neurology. 2015;84(6):617–622. doi: 10.1212/WNL.0000000000001238. PubMed DOI PMC

Slifer MA, Martin ER, Gilbert JR, Haines JL, Pericak-Vance MA. Resolving the relationship between apolipoprotein E and depression. Neurosci Lett. 2009;455(2):116–119. doi: 10.1016/j.neulet.2009.03.007. PubMed DOI PMC

Dissanayake AS, Tan YB, Bowie CR, Butters MA, Flint AJ, Gallagher D, et al. Sex modifies the associations of APOE ɛ4 with neuropsychiatric symptom burden in both at-risk and clinical cohorts of Alzheimer’s disease. J Alzheimers Dis. 2022;90(4):1571–1588. doi: 10.3233/JAD-220586. PubMed DOI

Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. JNP. 2000;12(2):233–239. doi: 10.1176/jnp.12.2.233. PubMed DOI